Inactive Instrument

Teligent

Equities

TLGT

US87960W2035

TELIGENT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 22, 2021 at 09:18 am EST

Item 8.01 Other Events

On November 24, 2020, Teligent, Inc. (the "Company") received notice from The Nasdaq Stock Market ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 ("Form 10-Q") with the Securities and Exchange Commission (the "SEC"). Upon filing of the Form 10-Q on December 31, 2020 with the SEC, the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) and this matter is now closed.

In addition, on July 28, 2020, the Company received notice from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) because the Company failed to maintain a minimum market value of publicly held shares of $15,000,000 for 30 consecutive trading days. On January 15, 2021, the Company received notice from Nasdaq confirming that for the last 10 consecutive trading days, the minimum market value of publicly held shares of the Company's common stock has been equal to or in excess of the $15,000,000 minimum market value of publicly held shares requirement for continued listing, as required by Nasdaq Listing Rule 5450(b)(2)(C). Accordingly, Nasdaq has determined that the Company has regained compliance with Nasdaq Listing Rule 5450(b)(2)(C) and this matter is now closed.

Also, as previously disclosed, the Company received notice from Nasdaq on December 4, 2020 that it was not in compliance with the minimum $1.00 bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule"). The Company continues to have until June 2, 2021 to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule on or before June 2, 2021, unless the Company files for and receives an extension to comply with the Bid Price Rule, the Company's common stock will be delisted from the Nasdaq Global Select Market. The Company intends to actively monitor the closing bid price of its listed shares of common stock and, as appropriate, will consider available options to resolve the deficiency and regain compliance with the Bid Price Rule.

The Company issued the press release attached hereto as Exhibit 99.1 related to the events discussed above.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.

Exhibit No. Exhibit Description

99.1 Press Release dated January 22, 2021

Latest news about Teligent

Teligent, Inc. Went Out of Business	22-07-26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	22-07-15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-05-25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	22-05-24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	22-04-29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-02-28	CI
Motion for Case Conversion Filed by Teligent, Inc.	22-02-22	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	22-02-09	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	22-02-03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-18	CI
London Shares to Open Higher as Traders Focus On Key Data	22-01-17	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	22-01-17	MT
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	22-01-16	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI

Chart Teligent

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company